Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Containing Centella sinensis mask group | Experimental | According to the random number table, both sides of the subjects' faces were randomly divided into the mask side and the control side (made of the same mask-like dressing), that is, one side of the face was applied with the Besuquan moisturizing repair mask, and the other side was applied with the control side. Patients were followed up on the day of treatment and 1, 2, 3, 4, 6 and 8 weeks after treatment. The specific methods are as follows: The patient applied 3 lobed membranes per week for the first month, and 2 pieces per week for 20 minutes each time for the second month. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Face mask containing Centella sinensis | Other | A half-face control test was used in this study. One side of the face was treated with a mask containing Asiaticum asiatica and the other side was treated with a mask without Asiaticum asiatica |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical erythema Score (CEA) | Clinical erythema score (CEA) was divided into no, mild, moderate and severe according to the severity of rosacea, corresponding to 0,1,2,3, respectively. | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. |
| Global Aesthetic Improvement Scale Score (GAIS) | The Global Aesthetic Improvement Scale (GAIS) score was evaluated by the treating physician and divided into four levels: very improved corresponding, substantial improvement, improvement, no change; Corresponding to the best beauty effect, significant improvement but not the best, significant improvement, no change; | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. |
| Melasma Area and Severity Rating (MASI) | The melasma Area and Severity Rating (MASI) is used to evaluate the severity of melasma. Melanin deposition was quantitatively evaluated from three aspects: area, color depth and color uniformity. Area weight: Forehead 30%, left cheek 30%, right cheek 30%, mandibular 10%, color plaque proportion (A) < 10% recorded 1 points, 10% ~ 29% recorded 2 points, 30% ~ 49% recorded 3 points, 50% ~ 69% recorded 4 points, 70% ~ 89% recorded 5 points, 90% ~ 100% recorded 6 points; Color depth (D), color uniformity (H) scores range from 0 to 4 points, no score 0 points, slight score 1 points, moderate score 2 points, obvious score 3 points, maximum score 4 points. MASI score = forehead [0.3A (D+H)]+ right cheek [0.3A (D+H)]+ left cheek [0.3A (D+H)]+ mandibular [0.1A (D+H)], score range 0 ~ 48, score was positively correlated with melanin deposition. | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Dermatology Quality of Life Score (DLQI) | The Dermatology Life Quality Score (DLQI) is scored by answering multiple questions in which patients self-rate the impact of their current illness on their lives over a period of one week. The answer is divided into four levels, very serious 3 points, severe 2 points, a little 1 point, no 0 points; ' | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. |
Not provided
Inclusion Criteria:
6.No medication was used within 1 month
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| jie dai | Contact | 86-025-52271117 | karry_dj@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nanjing First Hospital | Nanjing | Jiangsu | 210006 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012393 | Rosacea |
| D000152 | Acne Vulgaris |
| D008548 | Melanosis |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017486 | Acneiform Eruptions |
| D012625 | Sebaceous Gland Diseases |
| D017495 | Hyperpigmentation |
| D010859 | Pigmentation Disorders |
Not provided
Not provided